Literature DB >> 20687882

Bcl-2 family proteins as therapeutic targets.

Peter E Czabotar1, Guillaume Lessene.   

Abstract

The mitochondrion provides the stage for the interplay of molecular interactions that regulate apoptosis via the intrinsic pathway. The release of apoptogenic factors from this compartment constitutes a critical juncture in this apoptotic pathway. Regulation of the integrity of the outer mitochondrial membrane (OMM) is the task of the Bcl-2 family of proteins. A network of interactions between the various subgroups of the family decides the apoptotic fate of a cell and, as such, an imbalance within this network can lead to a variety of disease states. In particular, over-expression of pro-survival Bcl-2 family proteins is a hallmark of many cancers. Here we discuss recent advances in targeting the Bcl-2 family with both peptides and small molecules.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20687882     DOI: 10.2174/138161210793292429

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  14 in total

1.  Role of Caspase 8, Caspase 9 and Bcl-2 polymorphisms in papillary thyroid carcinoma risk in Han Chinese population.

Authors:  Ying-Xue Wang; Lei Zhao; Xiu-Yun Wang; Chang-Mei Liu; Su-Guo Yu
Journal:  Med Oncol       Date:  2011-11-26       Impact factor: 3.064

2.  Mutation to Bax beyond the BH3 domain disrupts interactions with pro-survival proteins and promotes apoptosis.

Authors:  Peter E Czabotar; Erinna F Lee; Geoff V Thompson; Ahmad Z Wardak; W Douglas Fairlie; Peter M Colman
Journal:  J Biol Chem       Date:  2011-01-03       Impact factor: 5.157

3.  Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway.

Authors:  M J Roy; A Vom; P E Czabotar; G Lessene
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

4.  Structure-Guided Rescaffolding of Selective Antagonists of BCL-XL.

Authors:  Michael F T Koehler; Philippe Bergeron; Edna F Choo; Kevin Lau; Chudi Ndubaku; Danette Dudley; Paul Gibbons; Brad E Sleebs; Carl S Rye; George Nikolakopoulos; Chinh Bui; Sanji Kulasegaram; Wilhelmus J A Kersten; Brian J Smith; Peter E Czabotar; Peter M Colman; David C S Huang; Jonathan B Baell; Keith G Watson; Lisa Hasvold; Zhi-Fu Tao; Le Wang; Andrew J Souers; Steven W Elmore; John A Flygare; Wayne J Fairbrother; Guillaume Lessene
Journal:  ACS Med Chem Lett       Date:  2014-03-21       Impact factor: 4.345

Review 5.  Oncogenic protein interfaces: small molecules, big challenges.

Authors:  Tracy L Nero; Craig J Morton; Jessica K Holien; Jerome Wielens; Michael W Parker
Journal:  Nat Rev Cancer       Date:  2014-03-13       Impact factor: 60.716

6.  Total synthesis of kingianin A.

Authors:  Hee Nam Lim; Kathlyn A Parker
Journal:  Org Lett       Date:  2012-12-28       Impact factor: 6.005

Review 7.  Role and treatment of mitochondrial DNA-related mitochondrial dysfunction in sporadic neurodegenerative diseases.

Authors:  Russell H Swerdlow
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

Review 8.  Targeting BCL2 in Chronic Lymphocytic Leukemia and Other Hematologic Malignancies.

Authors:  Fevzi F Yalniz; William G Wierda
Journal:  Drugs       Date:  2019-08       Impact factor: 9.546

9.  Structure-guided design of a selective BCL-X(L) inhibitor.

Authors:  Guillaume Lessene; Peter E Czabotar; Brad E Sleebs; Kerry Zobel; Kym N Lowes; Jerry M Adams; Jonathan B Baell; Peter M Colman; Kurt Deshayes; Wayne J Fairbrother; John A Flygare; Paul Gibbons; Wilhelmus J A Kersten; Sanji Kulasegaram; Rebecca M Moss; John P Parisot; Brian J Smith; Ian P Street; Hong Yang; David C S Huang; Keith G Watson
Journal:  Nat Chem Biol       Date:  2013-04-21       Impact factor: 15.040

10.  Abnormal expression of GADD45B in human colorectal carcinoma.

Authors:  Lisha Wang; Xiuying Xiao; Dali Li; Yayun Chi; Ping Wei; Yiqin Wang; Shujuan Ni; Cong Tan; Xiaoyan Zhou; Xiang Du
Journal:  J Transl Med       Date:  2012-10-30       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.